The FOPH regularly informs interested parties, particularly licence holders of drugs on the specialities list (SL/LS), on important developments relating to the list. These notifications are published here.
Exchange erates for SL/LS applications and reviews
The factors included in the FOPH’s assessment of the cost-effectiveness of drugs on the specialities list include the prices of drugs in nine reference countries in Europe (Denmark, Germany, the Netherlands, the UK, Austria, France, Sweden, Belgium and Finland). The FOPH converts foreign ex-factory prices into Swiss francs twice a year, on January 1 and July 1, at the exchange rates published here. These exchange rates are calculated on the basis of the average monthly exchange rates published by the Swiss National Bank for the previous twelve months.
Exchange rates for foreign price comparisons to the FOPH between 1 January 2021 and 30 June 2021.
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
List of pharmaceuticals subject to appeal
List of pharmaceuticals subject to an appeal against a decision of the FOPH.
Current FOPH notifications for licence holders and insurers related to drugs on the specialities list
Last modification 05.01.2021
Contact
Federal Office of Public Health FOPH
Health and Accident Insurance Directorate
Authorisation of Pharmaceuticals
Schwarzenburgstrasse 157
3003
Bern
Tel.
+41 58 462 90 35